Table 1. Studies supporting a beneficial role for IL-27 in murine colitis		
Model	Result	Reference
T cell transfer	Mucosal administration of IL-27 improves pathology and clinical disease	44
	IL-27Rα$^{-/-}$ renders Foxp3+ Tregs incapable of preventing enterocolitis	48
	IL-27Rα$^{-/-}$ on transferred T cells prevents the reduction of intestinal inflammation by IL-10-secreting B cells	25
DSS	Mucosal administration of IL-27 improves pathology and clinical disease	44, Andrews unpublished
	IL-27Rα$^{-/-}$ results in more severe colitis and reduced survival	47
	Concurrent IL-27Rα$^{-/-}$ in RAG$^{-/-}$ mice worsened colitis and decreased survival	47
	Elevated IL-27 in Fat-1 mice associated with decreased pathology	52
TNBS	Subcutaneous administration of IL-27 improves pathology	46
	Mucosal administration of IL-27 improves pathology and clinical disease	49
Citrobacter rodentium	IL-27 neutralization worsened colitis	43
Studies suggesting deleterious effects of IL-27 in murine colitis		
T cell transfer	IL-27Rα$^{-/-}$ on transferred T cells reduces inflammation and clinical disease	53
	IL-27Rα$^{-/-}$ in recipient mice prevents enterocolitis	54
DSS	IL-27Rα$^{-/-}$ mice develop less severe colitis	55
IL-10$^{-/-}$	Concurrent IL-27Rα$^{-/-}$ delays colitis and improves survival	56